Literature DB >> 3694201

Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage.

R Bayston1, C A Hart, M Barnicoat.   

Abstract

The results of treatment of 50 cases of ventriculitis associated with the use of cerebrospinal fluid shunts or external ventricular drains, and treated with intraventricular vancomycin, are reported. While the overall cure rate was 66% with four cases lost to follow-up, in those cases where treatment involved shunt removal, 20 mg vancomycin daily intraventricularly, and another appropriate systemic antibiotic, 22 of 24 cases were cured with two cases lost to follow-up. In those cases where the shunt was left in during treatment, results were poor and revision for blockage of the distal catheter of ventriculoperitoneal shunts was required in 44% of these. All five patients whose ventriculitis followed external ventricular drainage were cured. Despite relatively high trough levels of vancomycin in the cerebrospinal fluid, no evidence of toxicity was seen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3694201      PMCID: PMC1032551          DOI: 10.1136/jnnp.50.11.1419

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  Rifampin for CSF shunt infections caused by coagulase-negative staphylococci.

Authors:  J C Ring; K L Cates; K K Belani; T L Gaston; R J Sveum; S C Marker
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

2.  Intraventricular vancomycin: observations of tolerance and pharmacokinetics in two infants with ventricular shunt infections.

Authors:  A K Pau; R A Smego; M A Fisher
Journal:  Pediatr Infect Dis       Date:  1986 Jan-Feb

3.  The use of intraventricular vancomycin in the treatment of CSF shunt-associated ventriculitis.

Authors:  R Bayston; M Barnicoat; R E Cudmore; E J Guiney; N Gurusinghe; P M Norman
Journal:  Z Kinderchir       Date:  1984-12

4.  Prospective randomized study of therapy in cerebrospinal fluid shunt infection.

Authors:  H E James; J W Walsh; H D Wilson; J D Connor; J R Bean; P A Tibbs
Journal:  Neurosurgery       Date:  1980-11       Impact factor: 4.654

5.  Clinical pharmacology and efficacy of vancomycin in pediatric patients.

Authors:  U B Schaad; G H McCracken; J D Nelson
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

6.  Cerebrospinal fluid antibiotic levels during treatment of shunt infections.

Authors:  S L Wald; R L McLaurin
Journal:  J Neurosurg       Date:  1980-01       Impact factor: 5.115

7.  [Multiresistant Staphylococcus epidermidis septicemia with meningeal localization. Cure by general and intrathecal administration of vancomycin].

Authors:  D Raoult; J L Kohler; H Gallais; P Casanova
Journal:  Nouv Presse Med       Date:  1981-12-26

8.  Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases.

Authors:  M E Gombert; S H Landesman; M L Corrado; S C Stein; E T Melvin; M Cummings
Journal:  J Neurosurg       Date:  1981-10       Impact factor: 5.115

9.  Vancomycin treatment of cerebrospinal fluid shunt infections. Report of two cases.

Authors:  E B Visconti; G Peter
Journal:  J Neurosurg       Date:  1979-08       Impact factor: 5.115

10.  Enterococcal meningitis: combined vancomycin and rifampin therapy.

Authors:  J L Ryan; A Pachner; V T Andriole; R K Root
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

View more
  14 in total

Review 1.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

Review 3.  Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults.

Authors:  Karen Ng; Vincent H Mabasa; Ivy Chow; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

Review 4.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

5.  Production of extracellular slime by coryneforms colonizing hydrocephalus shunts.

Authors:  R Bayston; C Compton; K Richards
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

6.  Bactericidal activity of vancomycin in cerebrospinal fluid.

Authors:  M Nagl; C Neher; J Hager; B Pfausler; E Schmutzhard; F Allerberger
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 7.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

8.  Early diagnosis of external ventricular drainage infection: results of a prospective study.

Authors:  W Pfisterer; M Mühlbauer; T Czech; A Reinprecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

Review 9.  Central nervous system infections: a critical care approach.

Authors:  W C Ziai; R G Geocadin
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 6.030

10.  Current Practices of Intraventricular Antibiotic Therapy in the Treatment of Meningitis and Ventriculitis: Results from a Multicenter Retrospective Cohort Study.

Authors:  John J Lewin; Aaron M Cook; Cynthia Gonzales; David Merola; Ron Neyens; William J Peppard; Gretchen M Brophy; Lisa Kurczewski; Melissa Giarratano; Jason Makii; A Shaun Rowe; Eljim P Tesoro; Amber Zaniewski; Sarah Clark; Wendy C Ziai
Journal:  Neurocrit Care       Date:  2019-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.